Information sheet on the clinical study - SAPHIR
Main indication
Esophageal and gastric cancer
Study name (study type)
SAPHIR (registry platform)
Study sponsor
IOMEDICO
Registration number
ClinicalTrials.gov Identifier: NCT04290806
FOR BRIEF READERS:
Study for patients with esophageal and stomach cancer. Treatment data, questionnaires, and tissue samples from the patients’ tumors will be collected. This is an observational study and will not influence the treatment method prescribed by the physician.
DETAILED INFORMATION
Study Title
Registration Platform Esophageal and Gastric Cancer
Which conditions are being studied?
Esophageal and Gastric Cancer
Are specific subgroups of patients with one of the mentioned conditions being treated?
No
Background on the study medication
None
Study Procedure
Patients are asked to complete a questionnaire before the start of first-line treatment and then every 3 months for a maximum period of 2 years. All patients are asked to give their consent to the release of routinely collected tissue samples for future research projects.
Inclusion criteria
- Patients with metastatic ESCC (esophageal squamous cell carcinoma), GAC (gastric adenocarcinoma), or GEJAC (gastroesophageal junction adenocarcinoma)
- Planned palliative, first-line systemic therapy
- Patients who are 18 years of age or older
Exclusion criteria
- No prior systemic therapy for ESCC, GAC, or GELAC
Your contacts: Investigators at the center and contact information
Prof. Dr. Dimitri Flieger
Email: flieger@~@gp-ruesselsheim.de
Phone: 06142 88-1456
Staff members responsible at the study clinic
Heike Borchert (Study Coordinator)
Email: borchert@~@gp-ruesselsheim.de
Phone: 06142 88-1032